Cargando…
Myasthenia Gravis Induced by Nivolumab: A Case Report
Nivolumab is a programmed cell death receptor (PD-1) inhibitor therapy for aggressive cancers; however, it poses a risk of immune-related adverse side effects. We present a 73-year-old male with renal cell carcinoma who developed myasthenia gravis (MG) after being treated with nivolumab, proven by a...
Autores principales: | Mehta, Jeet J, Maloney, Eamon, Srinivasan, Sachin, Seitz, Patrick, Cannon, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690486/ https://www.ncbi.nlm.nih.gov/pubmed/29159009 http://dx.doi.org/10.7759/cureus.1702 |
Ejemplares similares
-
Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
por: Fukasawa, Yoko, et al.
Publicado: (2017) -
Nivolumab, a Double-Edged Sword: A Case Report of Nivolumab-Induced Myasthenia Gravis
por: Tahir, Nayha, et al.
Publicado: (2021) -
Relapsed Myasthenia Gravis after Nivolumab Treatment
por: Mitsune, Ayumi, et al.
Publicado: (2018) -
Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021) -
Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report
por: Chen, Yu-Hsiu, et al.
Publicado: (2017)